Raltegravir is used as part of combination antiretroviral therapy (ART), always taken alongside other anti-HIV medications rather than as a standalone treatment, in line with standard HIV management protocols. This combination approach reduces the risk of the virus developing resistance to any single drug and supports more effective, sustained viral suppression. It is prescribed for both treatment-naive patients starting therapy for the first time and treatment-experienced patients as part of ongoing HIV management.
The tablet is typically taken orally, with or without food, at the dose and frequency prescribed by the treating physician, and should be taken consistently at the same times each day to maintain effective drug levels. Adherence to the full prescribed regimen is essential — missed doses or inconsistent use can allow the virus to develop resistance, reducing the effectiveness of treatment over time.